"My 2021 Healthcare Resolution": 7 Johnson & Johnson Leaders Share Their Goals for Advancing Healthcare and Health Equity

My Resolution: Leverage 'Positive Disruption' This Year-and BeyondJennifer Taubert, Executive Vice President, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson

'At the Janssen Pharmaceutical Companies of Johnson & Johnson we know illnesses don't hit pause just because there's a global pandemic.

Whether they're battling cancer, tackling an autoimmune disease, facing mental health challenges or managing a serious condition like pulmonary arterial hypertension, people around the world rely on our transformational medicines every day. We know that, so we never stop delivering for our patients and customers.

While the COVID-19 pandemic has taken an enormous toll on individuals, governments and global economies, it has also catapulted us into new and innovative operating models to ensure we're able to meet our commitments to those we serve. Throughout the year, we rapidly scaled new ways of working-many supported by digital technology-that have proven extremely effective and have also helped increase efficiency.

We're seeing COVID-19 accelerate this type of 'positive disruption' across the healthcare ecosystem. I'm looking forward-in 2021 and beyond-to building on our learnings and expanding many of the innovative solutions we've been putting into practice across our business.

For example, in R&D, our scientists are integrating data science in our discovery and early research efforts to identify promising therapies more rapidly. We're also expanding the use of virtual clinical trials, utilizing digital technologies to monitor trial participants and offering new services, such as home delivery of study medicines. This can help pave the way for clinical trials to be more accessible to patients in the future.

In addition, since the outset of the pandemic, our Janssen commercial teams have scaled comprehensive virtual solutions worldwide to ensure patients and healthcare professionals receive the support they rely on. Using advanced analytics, we're able to identify the right customers and provide the information they need when making treatment decisions.

This includes engaging customers through integrated, 'omnichannel' platforms that help us optimize our interactions in ways they prefer. For example, when launching a new formulation of one of our oncology medicines, we used social media strategies to better reach our targeted audiences, and launched a new platform that provided us with an integrated, coordinated view of our customers' needs, leveraging real-time insights.

Product launches have also looked very different, requiring innovative approaches like virtual training for healthcare professionals. These types of virtual engagements have enabled us to maintain and strengthen our current relationships and also expand our reach to new customers.

Following the pandemic, we anticipate a greater focus on the importance of individual health and healthy societies, with enhanced focus on infectious diseases and vaccines. And, as we work to develop a robust vaccines business and leverage valuable lessons learned throughout the pandemic, we have an incredible opportunity to lead the way.

I'm excited to build on our momentum in 2021 by expanding our capabilities and building partnerships across the healthcare ecosystem to help create effective solutions with the potential to transform patients' lives.'